Product Description
Levobetaxolol is a cardioselective β-blocker that has been demonstrated to reduce intraocular pressure in patients affected with primary open-angle glaucoma and ocular hypertension. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium influx, which might confer a neuroprotective activity (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704505/)
Mechanisms of Action: ADRB1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: India | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Glaucoma, Open-Angle|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZK-LBL-2016-01 | P3 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2021-07-01 |
95% |